RxDoctor Payments Data

Jill Waldron, APRN

Gerontology · Slc, UTNPI 1083852677

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $11,894 of the $15,896 with a category attached, or 74.8%. Alnylam Pharmaceuticals Inc. accounts for 92.3% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $14,715, more than ten times the $61 reported in 2022. Among gerontology clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$15,896in general payments, 2019–2025

Across 46 payments — averaging $345.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alnylam Pharmaceuticals Inc.$15K
  • AstraZeneca$750
  • Abbott$250
  • Exeltis, USA Inc.$97
  • Merck$48
  • Novartis$31
  • plus $45 from 2 others

What the payments were for

  • Consulting fees$7505%
  • Speaking & faculty fees$11,89475%
  • Travel & lodging$1,59810%
  • Food & beverage$1,65410%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,896 in reported general payments places this provider in the 95th percentile of 26 gerontology providers in Utah.

See all gerontology providers in Utah

Medicare billing

Part B allowed, 2024
$42,596
Medicare patients
162
Services billed
689

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis43$979,620
FarxigaDapagliflozin Propanediol216$203,567
JardianceEmpagliflozin163$136,489
EliquisApixaban73$90,289
EntrestoSacubitril/Valsartan51$52,129
XareltoRivaroxaban26$25,112
Potassium Chloride212$7,922
Torsemide173$4,749
Eplerenone39$2,605
Bumetanide56$2,587
Midodrine Hcl54$2,465
Spironolactone253$1,801
Atorvastatin Calcium135$1,582
Metoprolol Succinate135$1,471
Pyridostigmine Bromide20$1,247

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$750$203,567216 claims
NovartisEntresto$31$52,12951 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 26 gerontology providers in Utah.

Other gerontology in Slc

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →